Peter Foley

25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

Bruce Strober, Richard B Warren, Peter Foley, Melinda Gooderham, Diamant Thaçi, Eva Cullen, Christopher Cioffi, Luke Peterson, Cynthia Madden, April Armstrong

Journal article  |  2021  |  Journal of the American Academy of Dermatology

28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

Andrew Blauvelt, Kenneth B Gordon, Christopher EM Griffiths, Kim A Papp, Peter Foley, Michael Song, Megan Miller, Yaung-Kaung Shen, Yin You, Paraneedharan Ramachandran, Kristian Reich

Journal article  |  2021  |  Journal of the American Academy of Dermatology

27078 Mediation analysis of independent treatment effect of guselkumab on health-related quality of life in patients with moderate to severe plaque-type psoriasis: Results from 2 phase 3 studies VOYAGE-1&2

April W Armstrong, Yan Liu, Nan Li, Kristian Reich, Peter Foley, Shu Li, Michael Song, Steven Fakharzadeh, Kim A Papp, Chenglong Han

Journal article  |  2021  |  Journal of the American Academy of Dermatology

27859 Maintenance of response through up to 5-years of continuous guselkumab treatment of psoriasis in the VOYAGE 2 phase 3 trial

Kristian Reich, April W Armstrong, Richard Langley, Ron Vender, Peter Foley, Michael Song, Yin You, Yaung-Kaung Shen, Kenneth B Gordon

Journal article  |  2021  |  Journal of the American Academy of Dermatology

27571 Dupilumab provides clinically meaningful responses in adults with moderate-to-severe atopic dermatitis (AD): Results from LIBERTY AD CHRONOS study

Jonathan I Silverberg, Eric L Simpson, Marjolein de Bruin&, undefined ;Weller, Peter Foley, Yoko Kataoka, Zhen Chen, Brad Shumel, Ana B Rossi, Debra Sierka, Jingdong Chao

Journal article  |  2021  |  Journal of the American Academy of Dermatology

26204 Hematology laboratory shift based on common terminology criteria in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily: Results from the 42-month BOLT study

Michael Migden, Karl Lewis, Alexander Guminski, Ralf Gutzmer, Carmen Loquai, Nicholas Squittieri, Peter Foley

Journal article  |  2021  |  Journal of the American Academy of Dermatology

26202 Antineoplastic therapy after discontinuation of sonidegib 200 mg in patients with advanced basal cell carcinoma: Results from the 42-month, randomized, double-blind BOLT study

Ralf Gutzmer, Alexander Guminski, Peter Foley, Anne Lynn S Chang, Karl Lewis, Nicholas Squittieri, Carmen Loquai

Journal article  |  2021  |  Journal of the American Academy of Dermatology

28096 Sustained improvement in general health-related quality of life and work productivity in patients with moderate to severe psoriasis treated with guselkumab: 5-year data from clinical trial VOYAGE 2

Kristian Reich, Kenneth B Gordon, Peter Foley, Mark Lomaga, Chenglong Han, Megan Miller, Yin You, Marc Alexander Radtke, Jashin J Wu, April W Armstrong

Journal article  |  2021  |  Journal of the American Academy of Dermatology

Combination treatment with monoclonal antibodies: Secukinumab, benralizumab and dupilumab for the combined management of psoriasis and severe asthma

Patrick D Mahar, Celia M Zubrinich, Nick Manuelpillai, Peter Foley

Journal article  |  2021  |  AUSTRALASIAN JOURNAL OF DERMATOLOGY

Biological disease-modifying agents have increasingly become available for the effective treatment of both cutaneous and non-cutan..

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

D Thaci, S Piaserico, RB Warren, AK Gupta, W Cantrell, Z Draelos, P Foley, A Igarashi, RG Langley, A Asahina, M Young, M Falqués, I Pau-Charles, AM Mendelsohn, SJ Rozzo, K Reich

Journal article  |  2021  |  Br J Dermatol

BACKGROUND: The phase III reSURFACE 1 and reSURFACE 2 (NCT01722331/NCT01729754) trials of the anti-interleukin-23p19 monoclonal an..